Composition, form of production and packaging
Lyophilizate for the preparation of a solution for iv and / m injection in the form of a white amorphous powder or porous mass; it is possible to smell the acetic acid.
1 amp.
dalargin 1 mg
Ampoules (5) - packings, cellular planimetric (2) - packs cardboard.
A solution for intravenous and / or injections in the form of a clear, colorless liquid; it is possible to smell the acetic acid.
1 ml
dalargin 1 mg
Auxiliary substances: sodium chloride, acetic acid, water d / and.
1 ml - ampoules (5) - packings of cellular contour (1) - packs cardboard.
1 ml - ampoules (5) - packings the cellular contour (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Antiulcer drug. Synthetic hexapeptide, analogue of leucine-enkephalin. Suppresses proteolysis and promotes the healing of stomach and duodenal ulcers. Has a moderate antisecretory activity, reduces the acidity of gastric juice. Suppresses the external secretion of the pancreas in response to various stimuli (including food, secretin).
When the pancreas is damaged, the drug reduces hyperfermentation, limits foci of necrosis and promotes their replacement with a full tissue, weakens the synthesis of proteolytic enzymes in the pancreas.
Has a slight hypotensive effect.
PHARMACOKINETICS
Data on the pharmacokinetics of the drug are not available.
INDICATIONS
- Stomach ulcer in the phase of exacerbation;
- Duodenal ulcer in the phase of exacerbation;
acute pancreatitis;
acute pancreatitis.
DOSING MODE
Immediately before use, the contents of the ampoule with the lyophilizate are dissolved in 1 ml of an isotonic sodium chloride solution.
The drug is given in / m or / in.
With gastric ulcer and duodenal ulcer in the phase of exacerbation, a single dose is 1-2 mg, the maximum daily dose is 5 mg. The course of treatment is 3-4 weeks.The total dose for the course of treatment is 30-50 mg.
In acute pancreatitis, the drug is administered iv in a dose of 2 mg, then 5 mg 1-2 times / day. The course of treatment 4-6 days.
With acute necrotic pancreatitis, iv injection of 5 mg 3-4 times / day (with an interval of 6-8 hours) is administered. The course of treatment is from 2 to 6 days.
SIDE EFFECT
From the side of the cardiovascular system: arterial hypotension.
Other: allergic reactions.
CONTRAINDICATIONS
- arterial hypotension;
- acute infectious diseases;
- Pregnancy;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The use of the drug during pregnancy is contraindicated.
The safety of the drug during lactation (breastfeeding) is not established.
APPLICATION FOR CHILDREN
The safety of the drug in children is not established.
SPECIAL INSTRUCTIONS
Use in Pediatrics
The safety of the drug in children is not established.
OVERDOSE
Data on drug overdose are not provided.
DRUG INTERACTION
Data on drug interaction of the drug are not provided.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored out of the reach of children.
Lyophilizate for the preparation of solution for iv and / m introduction should be stored in a dry, protected from light at a temperature of no higher than 20 В° C. Shelf life - 3 years.
Solution for intravenous and / or injection should be stored in a dry, protected from light at a temperature of 4 В° to 8 В° C. Shelf life - 3 years.
